Vibrato Aspiration System - Simple, Intuitive Approach to Clot Removal in Acute Pulmonary Embolism - a Safety & Feasibility Study
調査の概要
詳細な説明
The study objective is to evaluate the safety and effectiveness of the Vibrato™ Aspiration System Aspiration System (hereafter referred to as Vibrato™ Aspiration System) for aspiration mechanical thrombectomy in the treatment of acute PE.
The Vibrato™ Aspiration System is a vibration-assisted aspiration thrombectomy device including attributes designed to improve trackability, maintain a low-profile configuration, and operate without capital equipment. In addition, the Vibrato™ Aspiration System features a novel vibrating distal tip designed to enhance thrombus removal during aspiration while minimizing vascular injury. The vibrating mechanism may reduce procedure times, improve clot removal efficiency, and decrease the need for adjunctive interventions.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Shawn M Patterson
- 電話番号:7164323545
- メール:spatterson@egrethealthcareventure.com
研究連絡先のバックアップ
- 名前:Erin M Garcia
- 電話番号:716-863-2552
- メール:egarcia@egrethealthcareventures.com
研究場所
-
-
Greater Poland Voivodeship
-
Poznan、Greater Poland Voivodeship、ポーランド、61-848
- まだ募集していません
- Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Uniwersytecki Szpital Kliniczny
-
主任研究者:
- Aleksander Araszkiewicz, Professor, MD, PhD
-
-
Lesser Poland Voivodeship
-
Krakow、Lesser Poland Voivodeship、ポーランド、31-202
- 募集
- Krakowski Szpital Specjalistyczny im. św. Jana Pawła II
-
主任研究者:
- Grzegorz Kopeć, Professor, MD, PhD
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
Subjects must meet all following general inclusion criteria:
- Age ≥ 18 and ≤ 75 years.
- Clinical signs, symptoms, and presentation consistent with acute PE;
- PE symptom duration ≤ 14 days;
- CTA evidence (site determined) of proximal PE (filling defect in at least one main or interlobar pulmonary artery)
- RV/LV ratio of ≥ 0.9 on CTA as assessed by investigator (site determined).
- Systolic blood pressure ≥ 90 mmHg;
- Stable heart rate < 130 BPM prior to procedure;
- Patient is deemed medically eligible for interventional procedure(s), per institutional guidelines and clinical judgment
- Informed Consent Form signed
- Subject is willing and able to comply with all Clinical Investigation Plan required follow-up visit
Exclusion Criteria:
Subjects must not meet any of the following general exclusion criteria:
- Thrombolytic use within 30 days of baseline CT angiogram
- Pulmonary hypertension with peak pulmonary artery pressure > 70 mmHg by right heart catheterization (site determined)
- Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg;
- FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%;
- Hematocrit < 28%;
- Platelets < 100,000/ML;
- Serum creatinine > 1.8 mg/dL;
- International normalized ratio (INR) > 3;
- Major trauma injury severity score (ISS) > 15 within the past 14 days
- Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months, Pacemaker or Implantable Cardioverter Defibrillators;
- Cardiovascular or pulmonary surgery within last 7 days;
- Actively progressing cancer requiring chemotherapy
- Known bleeding diathesis or coagulation disorder;
- Left bundle branch block;
- History of severe or chronic pulmonary arterial hypertension;
- History of chronic left heart disease with left ventricular ejection fraction ≤ 30%;
- History of uncompensated heart failure;
- History of underlying lung disease that is oxygen dependent;
- History of chest irradiation;
- History of heparin-induced thrombocytopenia (HIT);
- Patients who are under intubation
- Any contraindication to systemic or therapeutic doses of heparin or anticoagulants;
- Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated;
- Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention;
- Life expectancy of < 90 days, as determined by Investigator;
- Female who is pregnant or nursing;
- Current participation in another investigational drug or device treatment study
- History of Hemorrhagic or Ischemic Stroke, including Transient Ischemic Attack, within last 90 days
- Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:デバイスの実現可能性
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Single arm study
Vibrato™ Aspiration System for aspiration mechanical thrombectomy in the treatment of acute pulmonary embolism.
|
Mechanical Thrombectomy for the treatment of Acute Pulmonary Embolism
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety Endpoint: Major Adverse Events
時間枠:48 hours
|
Major Adverse Events, a composite of:
|
48 hours
|
|
Efficacy Endpoint: Reduction in RV/LV Ratio
時間枠:48 hours
|
Reduction in RV/LV ratio from baseline to 48 hours or discharge by CT angiography
|
48 hours
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety Endpoint: Device-Related Death
時間枠:48 hours
|
Device-related death within 48 hours
|
48 hours
|
|
Safety Endpoint: Major Bleeding
時間枠:48 Hours
|
Major bleeding within 48 hours
|
48 Hours
|
|
Safety Endpoint: Device-Related Clinical Deterioration
時間枠:48 Hours
|
Device-related clinical deterioration within 48 hours
|
48 Hours
|
|
Safety Endpoint: Device-Related Pulmonary Vascular Injury
時間枠:48 Hours
|
Device-related pulmonary vascular injury within 48 hours
|
48 Hours
|
|
Safety Endpoint: Cardiac Injury
時間枠:48 Hours
|
Cardiac injury within 48 hours
|
48 Hours
|
|
Safety Endpoint: Any-Cause Mortality
時間枠:30 Days
|
Any-cause mortality within 30 days
|
30 Days
|
|
Safety Endpoint: Device-Related Serious Adverse Event
時間枠:30 Days
|
Device-related Serious Adverse Events (SAEs) within 30 days
|
30 Days
|
|
Safety Endpoint: Symptomatic Recurrence of Pulmonary Embolism
時間枠:30 Days
|
Symptomatic recurrence of Pulmonary Embolism (PE) within 30 days
|
30 Days
|
|
Efficacy Endpoint: Modified Miller Index Score
時間枠:48 Hours
|
Change in modified Miller Index Score (MMIS) between baseline and 48 hours post-procedure as assessed by CTA
|
48 Hours
|
|
Efficacy Endpoint: Change in Mean Pulmonary Artery Pressure
時間枠:Procedure
|
Change in mean pulmonary artery pressure measured invasively in the central pulmonary arteries before vs. after the endovascular procedure [measured in mmHg]
|
Procedure
|
|
Efficacy Endpoint: Procedural Change in Cardiac Index
時間枠:Procedure
|
Procedural change in cardiac index [measured in L/min/m^2]
|
Procedure
|
|
Efficacy Endpoint: Length of ICU Stay, Associated with Index Procedure
時間枠:30 Days
|
Length of stay in the ICU associated with the index procedure [measured in days]
|
30 Days
|
|
Efficacy Endpoint: Length of Total Hospital Stay
時間枠:30 Days
|
Length of total hospital stay [measured in days]
|
30 Days
|
|
Efficacy Endpoint: Post-Index Procedure Hospital Length of Stay
時間枠:30 Days
|
Post-index-procedure hospital length of stay [measured in days]
|
30 Days
|
|
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Mean Pressure
時間枠:Procedure
|
Procedural reduction in pulmonary artery mean pressure [measured in mmHg]
|
Procedure
|
|
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Systolic Pressure
時間枠:Procedure
|
Procedural reduction in pulmonary artery systolic pressure [measured in mmHg]
|
Procedure
|
|
Efficacy Endpoint: Reduction in Total Pulmonary Vascular Resistance
時間枠:Procedure
|
Procedural reduction in total pulmonary vascular resistance [measured in mmHg ⋅ min/L]
|
Procedure
|
|
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
時間枠:48 Hours
|
Change from baseline in Dyspnea severity by mMRC score at the 48-hour visit
|
48 Hours
|
|
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
時間枠:30 Days
|
Change from baseline in Dyspnea severity by mMRC score [Time Frame: at the 30 days visit]
|
30 Days
|
協力者と研究者
スポンサー
協力者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。